A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
Aged between 18 and 85 years;
GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT);
The maximum diameter of the GGO is bigger than 8mm and smaller than 3cm;
For single GGO: obvious progress was observed in pure GGO or the solid component of mixed ground glass nodules was more than or equal to 2 mm
Patients who participated in any drug and / or medical device clinical trials within one month before the trial
had severe disease conditions
allergy to narcotic drugs
had other autoimmune disease
Single group
Ablation therapy
Other interventionAblation therapy in the treatment of lung cancer presenting as ground-glass nodules
progression free survival
One year progression free survival after radiofrequency ablation of ground glass nodules
overall survival
overall survival after radiofrequency ablation of ground glass nodules
Click on the lead sponsor to view all of their trials.
